Hyperuricemia - Pipeline Insight, 2024

This “Hyperuricemia - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Hyperuricemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hyperuricemia Understanding

Hyperuricemia: Overview

Hyperuricemia is a condition where the uric acid in the blood level increases. The uric acid passes through the liver and enters the bloodstream. The normal upper limit is 6.8mg/dL, and anything over 7 mg/dL is considered saturated, and symptoms can occur. This elevated level is the result of increased production, decreased excretion of uric acid, or a combination of both processes.

Uric acid (2,6,8 trioxypurine-C5H4N4O3) is the result of purine breakdown. At the normal physiological pH of 7.4, uric acid circulates in the ionized form of urate. Purine metabolism mainly occurs in the liver, but it can also be produced in any other tissue that contains xanthine oxidase (intestines). About two-thirds of uric acid is excreted in the kidneys, and a third is excreted into the intestine. In the kidneys, it is filtered and secreted, and 90% is reabsorbed. Other mammals have lower uric acid levels due to the activity of uricase. This enzyme converts urate to the more water soluble form of allantoin. It is estimated as much as 21% of the general population and 25% of hospitalized patients have asymptomatic hyperuricemia. The most common complication of hyperuricemia is gout which is seen in 3.9% of the U.S. population. Hyperuricemia does not in itself indicate a pathological state because it is very prevalent in the general population.

Hyperuricemia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperuricemia pipeline landscape is provided which includes the disease overview and Hyperuricemia treatment guidelines. The assessment part of the report embraces, in depth Hyperuricemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Hyperuricemia R&D. The therapies under development are focused on novel approaches to treat/improve in Hyperuricemia.
• In November 2021, Allena Pharmaceuticals announced that its orally-administered, urate-degrading enzyme, ALLN-346, has received Fast Track designation from the U.S. Food and Drug Administration (FDA). ALLN-346 is in Phase 2 development for the treatment of hyperuricemia in gout patients with advanced chronic kidney disease (CKD).
• In March 2022, Atom Bioscience announced the results of a randomized double-blind, placebo-controlled Phase 2a clinical trial of ABP-671 to treat chronic gout. The study of APB-671 achieved its primary endpoint of reducing serum uric acid (sUA) levels to less than 6 mg/dL, which is below the clinically defined threshold of 7 mg/dL for hyperuricemia, the cause of gout. Significantly, no safety concerns were reported. Preliminary data suggest Atom’s compound reduces uric acid levels to prevent gout flare-ups without the adverse side effects of existing treatments.

This segment of the Hyperuricemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hyperuricemia Emerging Drugs

LR19074: LG Life SciencesLR19074 is a novel non-purine selective inhibitor of Xanthine Oxidase (XO). XO is needed to successively oxidize both hypoxanthine and xanthine to uric acid. Hence, this agent reduces uric acid concentrations in serum by inhibiting the production of uric acid by XO inhibition. LC350189 has the potential to address the unmet clinical needs for safety and efficacy in gout treatment. LC350189 showed good systemic exposures and sUA lowering effects with no significant safety concerns in Korean and the U.S. healthy volunteers.

NC-2500: Nippon ChemipharNC-2500 is a novel advanced xanthine oxidoreductase (XOR) inhibitor, having potential to reduce the risk of gout flare, one of major issues of current treatments for gout, and make a difference in gout treatment.

D-0502: InventisBioD-0120 is a novel oral selective uric acid transporter (URAT1) inhibitor being developed for the treatment of hyperuricemia and gout by blocking the reabsorption of uric acid (UA) within the renal proximal tubule, thereby reducing serum uric acid concentrations. As a novel URAT1 inhibitor, D-0120 is anticipated to have more potent serum UA reducing effect than the approved URAT1 inhibitor lesinurad, but with less toxicity and wider therapeutic window. The pharmacological potential of D-0120 for the treatment of hyperuricemia and gout was demonstrated in preclinical studies.

Hyperuricemia: Therapeutic Assessment

This segment of the report provides insights about the different Hyperuricemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hyperuricemia

There are approx. 15+ key companies which are developing the therapies for Hyperuricemia. The companies which have their Hyperuricemia drug candidates in the most advanced stage, i.e. Preclinical include LG Life Sciences.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hyperuricemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Antigouts

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hyperuricemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hyperuricemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperuricemia drugs.

Hyperuricemia Report Insights

• Hyperuricemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hyperuricemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hyperuricemia drugs?
• How many Hyperuricemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperuricemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hyperuricemia?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hyperuricemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Jiangsu Hengrui Medicine Co
• InventisBio
• AstraZeneca
• Atom Bioscience
• Allena Pharmaceuticals
• Arthrosi Therapeutics Australia
• LG Life Sciences
• Nippon Chemiphar

Key Products

• HR 091506
• Ruzinurad
• D 0120
• Verinurad
• ABP-671
• ALLN-346
• AR882
• LC350189
• NC-2500

This product will be delivered within 1-3 business days.